7. Primary Hepatic Cancer
- Janusz Jankowski MB ChB, MSc, MD, PhD, FRCP, FACG, AGAF4,5,6,
- Ernest Hawk MD, MPH7
Published Online: 15 NOV 2012
DOI: 10.1002/9781118423318.ch7
This edition first published 2013 © 2013 John Wiley & Sons Ltd.
Book Title

Handbook of Gastrointestinal Cancer
Additional Information
How to Cite
Said, A. H., Shetty, K., Li, Y., Blechacz, B., Hawk, E. and Mishra, L. (2012) Primary Hepatic Cancer, in Handbook of Gastrointestinal Cancer (eds J. Jankowski and E. Hawk), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118423318.ch7
Editor Information
- 4
Sir James Black Professor of Gastrointestinal Biology and Trials, Centre for Digestive Diseases, Barts and Th e London School of Medicine and Dentistry, London, UK
- 5
Consultant Gastroenterologist, University Hospitals of Leicester, Leicester, UK
- 6
James Black Senior Fellow, University of Oxford, Oxford, UK
- 7
Vice President and Division Head, Division of Cancer Prevention & Population Sciences, Boone Pickens Distinguished Chair for Early Prevention of Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Publication History
- Published Online: 15 NOV 2012
- Published Print: 12 JUL 2012
ISBN Information
Print ISBN: 9780470656242
Online ISBN: 9781118423318
- Summary
- Chapter
- References
Keywords:
- Hepatocellular carcinoma;
- viral hepatitis;
- cirrhosis;
- molecular therapy;
- biomarkers;
- BCLC staging classification;
- liver transplantation
Summary
Primary hepatic cancer or hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third leading cause of cancer mortality in the United States. It occurs commonly in the setting of cirrhosis and chronic liver disease, particularly viral hepatitis. Radiological studies are the primary modality utilized in the diagnosis of HCC, and serum markers as well as histology have additional roles. HCC is typically diagnosed at an advanced stage of disease, and the median survival time after diagnosis ranges between 6 and 20 months. However, if diagnosed at an early stage, patients suffering from HCC can receive effective curative options including surgical resection, tumor ablation, or liver transplantation. New insights into molecular pathways and targeted therapies carry significant promise for patients with HCC.
